An Alternative Dosing Schedule of Varenicline for Smoking Cessation
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT00835900
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 2
Terminated
- Conditions
- Leukemia
- Interventions
- Genetic: cytogenetic analysisGenetic: protein expression analysisOther: immunologic techniqueOther: pharmacological study
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00814164
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance
Not Applicable
Withdrawn
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00796874
Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer
Not Applicable
Terminated
- Conditions
- Breast CancerPrecancerous Condition
- Interventions
- Other: No InterventionDietary Supplement: Ground Flaxseed
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00794989
- Locations
- 🇺🇸
University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Roswell Cancer Park Institute, Buffalo, New York, United States
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT00736645
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer
Phase 2
Withdrawn
- Conditions
- Prostate Cancer
- Interventions
- Dietary Supplement: selenomethionineOther: placebo
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2012-02-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT00736164
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Not Applicable
Completed
- Conditions
- Lung Cancer
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00732563
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer
Not Applicable
Completed
- Conditions
- Lung CancerPrecancerous ConditionTobacco Use Disorder
- Interventions
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2018-06-04
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00690924
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT00683787
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx
- First Posted Date
- 2008-05-09
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 29
- Registration Number
- NCT00675233
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States